IL15 and celiac disease: For IL‐15 antagonism, active development is underway in related immune conditions, including ordesekimab/PRV‐015 in non‐responsive coeliac disease (NCT04424927; prior AMG‐714 study NCT02637141) and CALY‐002 in coeliac disease/eosinophilic oesophagitis (NCT04593251) [96, 97].